About Puma Biotechnology Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.pumabiotechnology.com/
Frequently Asked Questions
What is the 52-week range for PBYI?
The 52-week high is $10.1 and the 52-week low is $4.58.
What is the P/E ratio for PBYI?
The Price to Earnings (P/E) ratio is 18.78.
What is the dividend yield for PBYI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 20.85%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 11.55%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.30.
Analyst Recommendation Trends
Wall Street analyst consensus for PBYI over the last few months:
Latest PBYI News
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
LOS ANGELES, September 17, 2026--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
NERLYNX gives PBYI an established revenue stream that can support alisertibâs development into a potential second oncology franchise.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, September 03, 2026--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | WILSON TROY EDWARD | -5,000 | $9.1 | $45,500 |
| 2026-09-14 | Cesano Alessandra | -50,000 | - | - |
| 2026-09-14 | Cesano Alessandra | -62,150 | $9.123 | $566,994 |
| 2026-09-14 | Cesano Alessandra | +50,000 | $2.93 | $146,500 |
| 2026-07-06 | HUNT DOUGLAS M | -8,460 | $8.263 | $69,905 |
| 2026-07-06 | NOUGUES MAXIMO F | -9,386 | $8.263 | $77,557 |
| 2026-07-06 | AUERBACH ALAN H | -44,058 | $8.263 | $364,051 |
| 2026-06-12 | WILSON TROY EDWARD | -10,800 | $7.1989 | $77,748 |
| 2026-06-12 | Stuglik Brian M | -8,100 | $7.1989 | $58,311 |
| 2026-06-12 | Senderowicz Adrian | -27,000 | $7.1967 | $194,311 |
| 2026-06-12 | Dorval Allison | -11,610 | $7.1989 | $83,579 |
| 2026-06-12 | MOYES JAY M | -22,000 | $7.218 | $158,796 |
| 2026-06-11 | WILSON TROY EDWARD | +27,000 | - | - |
| 2026-06-11 | Stuglik Brian M | +27,000 | - | - |
| 2026-06-11 | Senderowicz Adrian | +27,000 | - | - |
| 2026-06-11 | Dorval Allison | +27,000 | - | - |
| 2026-06-11 | Cesano Alessandra | +27,000 | - | - |
| 2026-06-11 | MILLER MICHAEL PATRICK | +27,000 | - | - |
| 2026-06-11 | MOYES JAY M | +27,000 | - | - |
| 2026-02-18 | HUNT DOUGLAS M | +70,321 | - | - |
| 2026-02-18 | HUNT DOUGLAS M | +49,394 | - | - |
| 2026-02-18 | NOUGUES MAXIMO F | +66,541 | - | - |
| 2026-02-18 | NOUGUES MAXIMO F | +46,739 | - | - |
| 2026-02-18 | AUERBACH ALAN H | +227,474 | - | - |
| 2026-02-18 | AUERBACH ALAN H | +159,778 | - | - |
| 2026-01-07 | HUNT DOUGLAS M | -5,014 | $5.879 | $29,477 |
| 2026-01-07 | NOUGUES MAXIMO F | -6,405 | $5.879 | $37,655 |
| 2026-01-07 | AUERBACH ALAN H | -18,012 | $5.879 | $105,893 |
| 2026-01-06 | HUNT DOUGLAS M | -3,973 | $5.844 | $23,218 |
| 2026-01-06 | NOUGUES MAXIMO F | -4,540 | $5.844 | $26,532 |
| 2026-01-06 | AUERBACH ALAN H | -16,938 | $5.844 | $98,986 |
| 2025-11-11 | MILLER MICHAEL PATRICK | -20,000 | $4.8614 | $97,228 |